Matt Barkas

“I just want to ask, can you confirm what the exact percentage of your Alzheimer's agitation scripts or samples right now? And then since samples tend to run out in two or three weeks, any patient in June, July, a sample should be converting to an actual patient by now, you think?”

“Now, you provided more color today on the progress of your Phase I SAD-MAD studies and pain. Can you just remind us, like, what additional data you plan on sharing later this year for those programs?”

“And I just wanted to follow up on the revised guidance. Can you fundamentally talk about some of the push-pulls behind the continued growth and acceleration? And then are you aware of any other investigators sponsored or independent studies with Tareev that could be starting out over the next year?”

“I just wanted to see if you can give us a little bit of flavor on what other Phase III data analysis that you might share later this year, especially at AES conference in December, which can further showcase ACK's potential differentiation.”

“And you're quite right that we have seen a different instance of ALI in the clinical trial setting versus the real world setting. That's partly driven by the use of the research as a GLDH in the clinical trial setting, we'll be using that in cohort eight.”